Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRGX Stock Forecast 2026-2027
$4.47
Current Price
$219.57M
Market Cap
Buy 0
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to CRGX Price Targets
+56.6%
To High Target of $7.00
+56.6%
To Median Target of $7.00
+56.6%
To Low Target of $7.00
CRGX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+9.8%
1 Year Change
0.0%
Year-to-Date Change
-82.4%
From 52W High of $25.45
+49.0%
From 52W Low of $3.00
📊 TOP ANALYST CALLS
Did CRGX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CARGO Therapeutics is one of their latest high-conviction picks.
Latest CRGX Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CRGX has a neutral consensus with a median price target of $7.00 (ranging from $7.00 to $7.00). The overall analyst rating is Buy (6.0/10). Currently trading at $4.47, the median forecast implies a 56.6% upside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Asthika Goonewardene at Truist Securities, projecting a 56.6% upside. Conversely, the most conservative target is provided by Asthika Goonewardene at Truist Securities, suggesting a 56.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRGX Analyst Ratings
0
Buy
2
Hold
0
Sell
CRGX Price Target Range
Low
$7.00
Average
$7.00
High
$7.00
Current: $4.47
Latest CRGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 8, 2025 | Jefferies | Michael Yee | Hold | Maintains | $5.00 |
| Jan 30, 2025 | Chardan Capital | Geulah Livshits | Neutral | Downgrade | $N/A |
| Jan 30, 2025 | Piper Sandler | Biren Amin | Neutral | Downgrade | $4.00 |
| Jan 30, 2025 | HC Wainwright & Co. | Robert Burns | Neutral | Downgrade | $N/A |
| Jan 30, 2025 | William Blair | Sami Corwin | Market Perform | Downgrade | $N/A |
| Jan 30, 2025 | Jefferies | Michael Yee | Hold | Downgrade | $3.00 |
| Jan 30, 2025 | Truist Securities | Asthika Goonewardene | Hold | Downgrade | $7.00 |
| Jan 30, 2025 | JP Morgan | Brian Cheng | Underweight | Downgrade | $N/A |
| Nov 26, 2024 | William Blair | Sami Corwin | Outperform | Initiates | $N/A |
| Nov 15, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $33.00 |
| Nov 13, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $28.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $33.00 |
| Aug 13, 2024 | Piper Sandler | Biren Amin | Overweight | Maintains | $34.00 |
| Jul 22, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Initiates | $33.00 |
| Jul 8, 2024 | Chardan Capital | Geulah Livshits | Buy | Initiates | $28.00 |
| Jun 27, 2024 | Piper Sandler | Biren Amin | Overweight | Initiates | $37.00 |
| May 16, 2024 | Truist Securities | Asthika Goonewardene | Buy | Reiterates | $32.00 |
| Mar 22, 2024 | Jefferies | Michael Yee | Buy | Maintains | $32.00 |
| Dec 5, 2023 | Truist Securities | Asthika Goonewardene | Buy | Initiates | $34.00 |
| Dec 5, 2023 | TD Cowen | Tyler Van Buren | Outperform | Initiates | $N/A |
Cargo Therapeutics, Inc. (CRGX) Competitors
The following stocks are similar to CARGO Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cargo Therapeutics, Inc. (CRGX) Financial Data
Cargo Therapeutics, Inc. has a market capitalization of $219.57M with a P/E ratio of -1.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -65.8%.
Valuation Metrics
Market Cap
$219.57M
Enterprise Value
$-35,800,528
P/E Ratio
-1.2x
PEG Ratio
-0.6x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+116.8%
Current Ratio
12.4x
Debt/Equity
0.2x
ROE
-65.8%
ROA
-25.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cargo Therapeutics, Inc. (CRGX) Business Model
About Cargo Therapeutics, Inc.
What They Do
Develops novel cell therapies for cancer treatment.
Business Model
Cargo Therapeutics generates revenue by developing and commercializing advanced cell therapies, specifically engineered T-cells known as CAR T-cells, aimed at treating various types of cancer. The company focuses on harnessing cellular engineering to create transformative treatments that can address unmet medical needs in oncology.
Additional Information
The company operates in the rapidly evolving field of immunotherapy and personalized medicine, positioning itself as a key player in biotechnology. Its innovations in CAR T-cell therapies not only enhance treatment efficacy but also aim to improve patient outcomes in the face of life-threatening diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
167
CEO
Mr. Anup Radhakrishnan
Country
United States
IPO Year
2023
Website
cargo-tx.comCargo Therapeutics, Inc. (CRGX) Latest News & Analysis
Latest News
Quick Summary
The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for potential fiduciary duty breaches related to its deal with Concentra Biosciences, offering shareholders $4.379 per share.
Why It Matters
The investigation into CARGO for potential fiduciary breaches could impact its stock price and shareholder trust, affecting investment decisions and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for potential fiduciary duty breaches related to its transaction with Concentra Biosciences, offering shareholders $4.379 per share in cash.
Why It Matters
The investigation into CARGO for potential fiduciary breaches raises concerns about the integrity of the Concentra Biosciences deal, potentially impacting shareholder confidence and stock value.
Source: Business Wire
Market Sentiment:
Neutral
URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRGX, HSON, BRZH, and ENZB
8 months ago
Quick Summary
Monteverde & Associates is investigating CARGO Therapeutics' sale to Concentra Biosciences for $4.379 per share, plus contingent rights related to future cash and asset sales.
Why It Matters
CARGO Therapeutics' sale terms may impact shareholder value, given the potential contingent value rights linked to future asset sales, influencing investment decisions and market sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CARGO Therapeutics is set to be acquired by Concentra Biosciences for $4.379 per share in cash, plus a contingent value right for 100% of its closing net cash.
Why It Matters
The investigation into CARGO Therapeutics' sale could indicate potential issues with the deal, affecting share value and investor confidence in the transaction's completion and fairness.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
CARGO Therapeutics has agreed to be acquired by Concentra Biosciences for $4.379 per share, plus a contingent value right linked to future cash and product sales.
Why It Matters
CARGO's merger with Concentra at $4.379 per share, plus contingent value rights, indicates potential upside for shareholders and reflects market confidence in CARGO's pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Class Action Attorney Juan Monteverde is investigating CARGO Therapeutics' sale to Concentra Biosciences for $4.379 per share, plus contingent rights tied to future cash and asset sales.
Why It Matters
The investigation into CARGO Therapeutics' sale could impact share prices and investor sentiment, highlighting potential legal risks and financial recoveries related to the transaction.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CRGX Stock
What is Cargo Therapeutics, Inc.'s (CRGX) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Cargo Therapeutics, Inc. (CRGX) has a median price target of $7.00. The highest price target is $7.00 and the lowest is $7.00.
Is CRGX stock a good investment in 2026?
According to current analyst ratings, CRGX has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRGX stock?
Wall Street analysts predict CRGX stock could reach $7.00 in the next 12 months. This represents a 56.6% increase from the current price of $4.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cargo Therapeutics, Inc.'s business model?
Cargo Therapeutics generates revenue by developing and commercializing advanced cell therapies, specifically engineered T-cells known as CAR T-cells, aimed at treating various types of cancer. The company focuses on harnessing cellular engineering to create transformative treatments that can address unmet medical needs in oncology.
What is the highest forecasted price for CRGX Cargo Therapeutics, Inc.?
The highest price target for CRGX is $7.00 from Asthika Goonewardene at Truist Securities, which represents a 56.6% increase from the current price of $4.47.
What is the lowest forecasted price for CRGX Cargo Therapeutics, Inc.?
The lowest price target for CRGX is $7.00 from Asthika Goonewardene at Truist Securities, which represents a 56.6% increase from the current price of $4.47.
What is the overall CRGX consensus from analysts for Cargo Therapeutics, Inc.?
The overall analyst consensus for CRGX is neutral. Out of 8 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are CRGX stock price projections?
Stock price projections, including those for Cargo Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 3:49 AM UTC